EGFR and neoplasm: Several other glyco-engineered antibodies targeting a variety of different tumor associated antigens like CD19, CD20, EGFR, and GD2 are currently investigated in early clinical studies (Robak, 2009; Navid et al., 2010; Paz-Ares et al., 2011; Ward et al., 2011).